PUBLISHER: DelveInsight | PRODUCT CODE: 1226662
PUBLISHER: DelveInsight | PRODUCT CODE: 1226662
"Lerociclib Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about Lerociclib for ER +ve HER2-ve Breast Cancer in the United States. A detailed picture of the Lerociclib for ER+ve HER2-ve Breast Cancer in the United States for the study period 2019-2032 is provided in this report along with a detailed description of the Lerociclib for ER+ve HER2-ve Breast Cancer. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the Lerociclib market forecast, analysis for ER+ve HER2-ve Breast Cancer in the United States, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in ER+ve HER2-ve Breast Cancer.
Lerociclib (EQ132) is a novel, oral, potent, and selective small-molecule cyclin-dependent kinase (CDK) 4/6 inhibitor that has been demonstrated in a Phase I clinical trial in patients with metastatic breast cancer to be highly active in combination with estrogen receptor antagonists with an acceptable tolerability profile. Lerociclib is being studied in a Phase II clinical trial to treat HR+/HER2- metastatic breast cancer.
At the San Antonio Breast Cancer Symposium (SABCS) in December 2019, G1 reported preliminary Phase I/II clinical data in HR+/HER2- metastatic breast cancer.
G1 entered into separate, exclusive agreements with EQRx (rights for the US, Europe, Japan, and all markets outside Asia-Pacific) and Genor (rights for Asia-Pacific, excluding Japan) for the development and commercialization of lerociclib in all indications. EQRx and Genor are responsible for all costs related to the development and commercialization of lerociclib in their respective territories.
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
Lerociclib Analytical Perspective by DelveInsight
This report provides a detailed market assessment of Lerociclib in ER+ve HER2-ve Breast Cancer in the United States. This segment of the report provides forecasted sales data from 2026 to 2032.
The report provides the clinical trials information of Lerociclib in ER+ve HER2-ve Breast Cancer covering trial interventions, trial conditions, trial status, start and completion dates.
Key Questions